Overview

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

This open, single arm, explorative study aims to investigate the evolution of gastrointestinal adverse events after switch from MMF to EC-MPS in organ transplanted patients suffering from gastrointestinal adverse events while on MMF therapy.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Mycophenolate mofetil
Mycophenolic Acid